GT Biopharma (GTBP) Stock: Buy, Sell, or Hold?
GTBP - GT Biopharma Inc. Common Stock
$5.07
-0.39 (-7.14%)
▼
5d:
-24.22%
30d:
-26.42%
90d:
+1500.88%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 13, 2026
17d
Get Alerted When GTBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GTBP is down 24.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GTBP is down 24.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GTBP is currently trading at $5.07, which is considered oversold relative to its 30-day fair value range of $5.91 to $7.17.
Technical Outlook: Technically, GTBP is in a strong uptrend. The price is currently testing key support at $5.07. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $75.00 (+1379.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GTBP is in a strong uptrend. The price is currently testing key support at $5.07. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $75.00 (+1379.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.91 -
$7.17
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.1%)
- BULLISH: Trading 1379.3% below Wall St target ($75.00)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.91 -
$7.17
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.07
Resistance Level
$7.50
Current Trend
Strong Uptrend
Technical data as of
Oct 26, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.63
Wall Street Target
$75.00
(+1379.3%)
Share & Embed Analysis
Last updated: October 26, 2026 6:19 PM ET
Data refreshes hourly during market hours. Next update: 7:19 PM
Data refreshes hourly during market hours. Next update: 7:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GTBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$368 | 58 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 43 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
19 analysts |
$141 | 71 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 40 HOLD |
